JP2015520229A5 - - Google Patents

Download PDF

Info

Publication number
JP2015520229A5
JP2015520229A5 JP2015518386A JP2015518386A JP2015520229A5 JP 2015520229 A5 JP2015520229 A5 JP 2015520229A5 JP 2015518386 A JP2015518386 A JP 2015518386A JP 2015518386 A JP2015518386 A JP 2015518386A JP 2015520229 A5 JP2015520229 A5 JP 2015520229A5
Authority
JP
Japan
Prior art keywords
amount
composition
administered
vitamin
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015518386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520229A (ja
Filing date
Publication date
Priority claimed from US13/530,673 external-priority patent/US9040082B2/en
Application filed filed Critical
Publication of JP2015520229A publication Critical patent/JP2015520229A/ja
Publication of JP2015520229A5 publication Critical patent/JP2015520229A5/ja
Pending legal-status Critical Current

Links

JP2015518386A 2012-06-22 2012-11-30 神経心理学的障害の治療用の組成物および方法 Pending JP2015520229A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/530,673 US9040082B2 (en) 2011-06-24 2012-06-22 Compositions and methods for treatment of chronic fatigue
US13/530,673 2012-06-22
PCT/US2012/067347 WO2013191724A1 (en) 2012-06-22 2012-11-30 Compositions and methods for treatment of neuropsychological deficits

Publications (2)

Publication Number Publication Date
JP2015520229A JP2015520229A (ja) 2015-07-16
JP2015520229A5 true JP2015520229A5 (enExample) 2015-12-17

Family

ID=49769962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015518386A Pending JP2015520229A (ja) 2012-06-22 2012-11-30 神経心理学的障害の治療用の組成物および方法

Country Status (6)

Country Link
US (2) US9040082B2 (enExample)
EP (1) EP2879495A4 (enExample)
JP (1) JP2015520229A (enExample)
AU (1) AU2012382949A1 (enExample)
CA (1) CA2849968A1 (enExample)
WO (1) WO2013191724A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040082B2 (en) * 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
ES2605495T3 (es) 2013-11-08 2017-03-14 Eli Lilly And Company Solución de atomoxetina
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
US12472158B2 (en) 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
WO2023281095A1 (en) * 2021-07-08 2023-01-12 Nls Pharmaceutics Ag Lauflumide and derivatives thereof for treating chronic fatigue syndrome and myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs)
GB202214775D0 (en) * 2022-10-07 2022-11-23 Nicoventures Trading Ltd Oral product

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542123A (en) 1982-01-11 1985-09-17 Massachusetts Institute Of Technology Composition and method for increasing brain tyrosine levels
US6451341B1 (en) 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5096712A (en) 1990-03-06 1992-03-17 Interneuron Pharmaceuticals, Inc. Method for enhancing performance so as to improve vigor and decrease fatigue, confusion, tension, and anxiety
US5292538A (en) 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5948443A (en) 1996-02-23 1999-09-07 Medical Doctor's Research Institute, Inc. Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease
US5895652A (en) 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
EP1021177A4 (en) 1997-02-04 2002-05-15 John V Kosbab COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US5916912A (en) 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress
US6048846A (en) 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US6191162B1 (en) 1998-05-28 2001-02-20 Medical Research Institute Method of reducing serum glucose levels
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
US20030206895A1 (en) 1998-11-13 2003-11-06 Sigma-Tau Healthscience S.P.A. Antioxidant composition comprising propionyl L-carnitine and a flavonoid against throm-bosis and atherosclerosis
AU4988000A (en) 1999-05-07 2000-11-21 Trustees Of Tufts College Immune stimulating dietary supplement and methods of use thereof
KR20020016833A (ko) 1999-06-15 2002-03-06 뉴트리-로직스, 인크. 발병 감소에 유용한 영양 제제, 관련 치료 방법 및 성분스크리닝 방법
US6103756A (en) 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
WO2001021208A1 (en) 1999-09-23 2001-03-29 Juvenon Corporation Nutritional supplement for increased energy and stamina
WO2001026642A2 (en) * 1999-10-08 2001-04-19 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
US20020155163A1 (en) 1999-12-27 2002-10-24 Samuel D. Benjamin Integrated multi-vitamin and mineral combination
US6458384B2 (en) 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
US6579544B1 (en) 2000-05-31 2003-06-17 Nutriex, L.L.C. Method for supplementing the diet
US6423349B1 (en) 2000-08-24 2002-07-23 Baxter International, Inc. Therapeutic nutrient composition for pre and post elective surgery
US20070117869A1 (en) 2000-11-01 2007-05-24 Cognition Pharmaceuticals Llc Methods for treating coginitive impairment and improving cognition
WO2005000203A2 (en) 2001-10-31 2005-01-06 Sention, Inc. Methods for treating cognitive impairment and improving cognition
US6733797B1 (en) 2000-11-15 2004-05-11 William K. Summers Neuroceutical for improving memory and cognitive abilities
US20020193323A1 (en) 2000-11-22 2002-12-19 Inna Yegorova Compositions and methods for promoting a healthy cardiovascular system and enhancing blood flow
US6300377B1 (en) 2001-02-22 2001-10-09 Raj K. Chopra Coenzyme Q products exhibiting high dissolution qualities
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
ES2269671T3 (es) 2001-04-25 2007-04-01 Cobalz Limited Composiciones medicas para su uso en el tratamiento o la prevencion de una insuficiencia de vitamina b12 funcional.
US20020165281A1 (en) * 2001-04-26 2002-11-07 Assa Weinberg Treatment of anoxic encephalophathy by administration of N-acetylcystein
CA2752782A1 (en) 2001-07-11 2003-01-23 Cns Response, Inc. Electroencephalography based systems and methods for selecting therapies and predicting outcomes
US6541043B2 (en) 2001-08-28 2003-04-01 Dexgen Pharmaceuticals, Inc. Method and synergistic composition for treating attention deficit/hyperactivity disorder
US20030049272A1 (en) 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US20030068391A1 (en) 2001-10-04 2003-04-10 Harris Dennis H. Ingestible nerve and circulatory nutritional formulation
EP1304048B1 (en) 2001-10-22 2004-09-22 Ivo Pera Composition to reduce or quit smoking addiction
GB2381451A (en) 2001-11-01 2003-05-07 New Technology Res Ltd Pharmaco-dietary preparation having nutrition-supplementing and nutrition-enhancing effect
WO2003090673A2 (en) 2002-04-22 2003-11-06 Rtc Research & Development, Llc. Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals
US7585523B2 (en) 2002-08-27 2009-09-08 Targeted Medical Pharma Composition and method to augment and sustain neurotransmitter production
US7968125B2 (en) 2003-04-08 2011-06-28 Janeel Henderson Energy generating composition
US20050058672A1 (en) 2003-09-14 2005-03-17 Bioderm Research Baby Care Skin Protectant Compositions for Diaper Rash
US20070237834A1 (en) 2003-04-18 2007-10-11 Bioderm Research Zinc Zeolite for the Treatment for Diaper Rash (Diaper Dermatitis)
MXPA05012614A (es) * 2003-05-23 2006-08-23 Sention Inc Metodos para el tratamiento del deterioro cognitivo y mejorar la cognicion.
US8211873B2 (en) 2003-08-29 2012-07-03 Island Kinetics, Inc. Antiaging chirally-correct mitoprotectant amino acid and peptide complexes
AU2003300167B2 (en) 2003-12-31 2010-09-16 K-Pax Vitamins, Inc. Nutrient compositions and methods for enhanced effectiveness of the immune system
HRP20160455T1 (hr) 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
MX2007006324A (es) 2004-11-29 2007-10-17 Aloecorp Inc Deshidratacion de combinaciones de alimentos.
US7250181B2 (en) 2005-01-19 2007-07-31 Natreon, Inc. Polyherbal compositions and methods for treating viral infections
US7776915B2 (en) 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
WO2006112283A1 (ja) * 2005-04-13 2006-10-26 Riken Vitamin Co., Ltd. 抗疲労剤
US20060257502A1 (en) 2005-05-11 2006-11-16 Jiankang Liu A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders
US7645742B2 (en) 2005-06-22 2010-01-12 Advocare International, L.P. Composition for enhancing cellular energy
US7893070B2 (en) 2005-08-15 2011-02-22 Provimi Holding B.V. Method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion
US7976879B2 (en) 2005-11-04 2011-07-12 Roizen Michael F Nutritional supplement product to suppress age-related decline in cognitive capacity and other aging functions
JP4904795B2 (ja) * 2005-12-06 2012-03-28 大正製薬株式会社 疲労改善剤組成物
US7919135B2 (en) 2006-03-13 2011-04-05 The Hershey Company Steeped cocoa beverages
US7972633B2 (en) 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
EP2109465B1 (en) 2007-02-08 2012-04-11 Kempharm, Inc. Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
US8187647B2 (en) 2008-06-13 2012-05-29 BioClinical Development, Inc. Edible energy composition
WO2009098697A1 (en) 2008-02-08 2009-08-13 Dexxon Ltd. Modafinil and sildenafil dosage forms
WO2009108999A1 (en) 2008-03-03 2009-09-11 Ross Stewart Grant Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
US20090325999A1 (en) 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
US8642095B2 (en) 2008-09-30 2014-02-04 Visalus Holdings, Llc Dietary composition and method of using the same
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
JP5811545B2 (ja) * 2010-06-24 2015-11-11 国立研究開発法人理化学研究所 疲労のバイオマーカーおよびその利用
CN113142581B (zh) 2010-12-23 2025-07-22 阿马曾提斯公司 用于改善线粒体功能的组合物和方法
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue

Similar Documents

Publication Publication Date Title
AR082150A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio
JP2014522817A5 (enExample)
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
FI3478712T3 (fi) Anti-N3pGlu beeta-amyloidipeptidi -vasta-aineita ja niiden käyttöjä
JP2014509659A5 (enExample)
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
JP2012530779A5 (enExample)
JP2010270124A5 (enExample)
JP2015529234A5 (enExample)
RU2017119222A (ru) Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
BR112014005389A8 (pt) Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
JP2014512354A5 (enExample)
HK1200716A1 (zh) 使用胞苷類似物的口服製劑治療癌症的方法
JP2014530821A5 (enExample)
JP2013509411A5 (enExample)
JP2014500295A5 (enExample)
JP2015515985A5 (enExample)
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
BR112014003704A2 (pt) moduladores ror gama
JP2020534270A5 (enExample)
JP2013518914A5 (enExample)
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
JP2016507500A5 (enExample)